Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) CEO Robert Duggan acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was bought at an average price of $14.60 per share, with a total value of $1,460,000.00. Following the acquisition, the chief executive officer directly owned 25,824,474 shares of the company’s stock, valued at $377,037,320.40. The trade was a 0.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Summit Therapeutics Trading Down 1.5%
NASDAQ SMMT opened at $14.84 on Friday. The stock has a 50-day simple moving average of $19.02 and a 200 day simple moving average of $17.47. The company has a market capitalization of $11.52 billion, a PE ratio of -9.28 and a beta of -1.32. Summit Therapeutics PLC has a 12 month low of $13.83 and a 12 month high of $30.98.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last released its quarterly earnings data on Friday, May 1st. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. As a group, sell-side analysts predict that Summit Therapeutics PLC will post -1.17 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on SMMT
Institutional Trading of Summit Therapeutics
A number of institutional investors have recently modified their holdings of SMMT. AQR Capital Management LLC lifted its holdings in shares of Summit Therapeutics by 5.0% in the first quarter. AQR Capital Management LLC now owns 65,623 shares of the company’s stock valued at $1,266,000 after purchasing an additional 3,134 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Summit Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after purchasing an additional 694 shares in the last quarter. Creative Planning lifted its holdings in shares of Summit Therapeutics by 6.7% in the second quarter. Creative Planning now owns 21,390 shares of the company’s stock valued at $455,000 after purchasing an additional 1,336 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Summit Therapeutics by 33.8% in the second quarter. Legal & General Group Plc now owns 26,367 shares of the company’s stock valued at $561,000 after purchasing an additional 6,662 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Summit Therapeutics in the second quarter valued at about $132,000. 4.61% of the stock is currently owned by institutional investors.
About Summit Therapeutics
Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.
Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.
Read More
- Five stocks we like better than Summit Therapeutics
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
